{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:38:26Z","timestamp":1776087506789,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jgo.2017.12.001","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:50Z","timestamp":1515456050000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of mantle cell lymphoma in older adults"],"prefix":"10.1016","volume":"9","author":[{"given":"Daniel F.","family":"Pease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki A.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2017.12.001_bb0005","series-title":"World Health Organization classification of Tumours of Haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"4","key":"10.1016\/j.jgo.2017.12.001_bb0010","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2017.12.001_bb0015","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","article-title":"Mantle cell lymphoma epidemiology: a population-based study in France","volume":"93","author":"Leux","year":"2014","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.jgo.2017.12.001_bb0020","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.22715","article-title":"Leukemic involvement is a common feature in mantle cell lymphoma","volume":"109","author":"Ferrer","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2017.12.001_bb0025","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2017.12.001_bb0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ajcp\/100.4.373","article-title":"Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features","volume":"100","author":"Zukerberg","year":"1993","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.jgo.2017.12.001_bb0035","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0046-8177(95)90090-X","article-title":"Expression of cyclin D1 protein in centrocytic\/mantle cell lymphomas with and without rearrangement of the BCL1\/cyclin D1 gene","volume":"26","author":"Swerdlow","year":"1995","journal-title":"Hum Pathol"},{"issue":"20","key":"10.1016\/j.jgo.2017.12.001_bb0040","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jgo.2017.12.001_bb0045","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2017.12.001_bb0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.semcancer.2011.09.006","article-title":"The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies","volume":"21","author":"Burger","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.jgo.2017.12.001_bb0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10044","key":"10.1016\/j.jgo.2017.12.001_bb0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jgo.2017.12.001_bb0065","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.jgo.2017.12.001_bb0070","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.05.001","article-title":"Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy","volume":"64","author":"Wedding","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"10.1016\/j.jgo.2017.12.001_bb0080","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2017.12.001_bb0085","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the lymphoma Italian foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0090","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/asheducation-2016.1.425","article-title":"Treatment of the elderly patient with mantle cell lymphoma","volume":"2016","author":"Soubeyran","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8878","key":"10.1016\/j.jgo.2017.12.001_bb0095","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0140-6736(93)92884-V","article-title":"Comprehensive geriatric assessment: a meta-analysis of controlled trials","volume":"342","author":"Stuck","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jgo.2017.12.001_bb0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdu210","article-title":"Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations\u2020","volume":"26","author":"Decoster","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","article-title":"Performance of two geriatric screening tools in older patients with cancer","volume":"32","author":"Kenis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2017.12.001_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jgo.2016.01.004","article-title":"Detection of frailty in elderly cancer patients: improvement of the G8 screening test","volume":"7","author":"Petit-Mon\u00e9ger","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2017.12.001_bb0115","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.jgo.2017.12.001_bb0120","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a prediction tool for chemotherapy toxicity in older adults with cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2017.12.001_bb0125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.jgo.2017.12.001_bb0130","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","article-title":"Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma","volume":"27","author":"Eve","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jgo.2017.12.001_bb0135","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jgo.2017.12.001_bb0140","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2017.12.001_bb0145","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1016\/j.jgo.2017.12.001_bb0150","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jgo.2017.12.001_bb0155","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jgo.2017.12.001_bb0160","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2017.12.001_bb0165","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2017.12.001_bb0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3109\/10428194.2013.815353","article-title":"Indolent mantle cell lymphoma","volume":"55","author":"Hsi","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jgo.2017.12.001_bb0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"Suppl","key":"10.1016\/j.jgo.2017.12.001_bb0180","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.clml.2014.04.013","article-title":"Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the surveillance, epidemiology and end results database","volume":"14","author":"Guru Murthy","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.jgo.2017.12.001_bb0185","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/annonc\/mdx334","article-title":"Early-stage mantle cell lymphoma: a retrospective analysis from the international lymphoma radiation oncology group (ILROG)","volume":"28","author":"Dabaja","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2017.12.001_bb0190","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2017.12.001_bb0195","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdr035","article-title":"Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Jantunen","year":"2012","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.jgo.2017.12.001_bb0205","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0210","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"9873","key":"10.1016\/j.jgo.2017.12.001_bb0215","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jgo.2017.12.001_bb0220","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jgo.2017.12.001_bb0225","article-title":"First-line treatment of iNHL or MCL patients with BR or R-CHOP\/R-CVP: results of the BRIGHT 5-year follow-up study","volume":"35","author":"Flinn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2017.12.001_bb0230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2017.12.001_bb0235","article-title":"Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab","author":"Verriere","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2017.12.001_bb0240","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2017.12.001_bb0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2017.12.001_bb0250","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0255","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"issue":"Supplemental S2","key":"10.1016\/j.jgo.2017.12.001_bb0260","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hon.2437_131","article-title":"First line treatment by the RIBVD regimen elicits high clinical and molecular response rates and prolonged survival in elderly MCL patients; final results of a LYSA group trial","volume":"35","author":"Gressin","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jgo.2017.12.001_bb0265","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma >65years, the Nordic lymphoma group phase I+II trial NLG-MCL4","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jgo.2017.12.001_bb0270","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","article-title":"Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS","volume":"23","author":"Houot","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2017.12.001_bb0275","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2017.12.001_bb0285","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0290","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the north central cancer treatment group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2017.12.001_bb0295","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2011.575489","article-title":"Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma","volume":"52","author":"Spurgeon","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.jgo.2017.12.001_bb0300","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jgo.2017.12.001_bb0305","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10020","key":"10.1016\/j.jgo.2017.12.001_bb0310","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jgo.2017.12.001_bb0315","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3109\/10428194.2016.1169408","article-title":"Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma","volume":"57","author":"Lee","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jgo.2017.12.001_bb0320","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.14321","article-title":"Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders","volume":"175","author":"Mulligan","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jgo.2017.12.001_bb0325","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1080\/10428194.2016.1251592","article-title":"Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in routine clinical practice","volume":"58","author":"Finnes","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2017.12.001_bb0330","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jgo.2017.12.001_bb0335","author":"Acalabrutinib prescribing information"},{"issue":"11","key":"10.1016\/j.jgo.2017.12.001_bb0340","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jgo.2017.12.001_bb0345","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2017.12.001_bb0350","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2017.12.001_bb0355","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2017.12.001_bb0360","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2017.12.001_bb0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2017.12.001_bb0370","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2017.12.001_bb0375","author":"U.S. National Library of Medicine"},{"key":"10.1016\/j.jgo.2017.12.001_bb0380","author":"U.S. National LIbrary of Medicine"},{"issue":"S2","key":"10.1016\/j.jgo.2017.12.001_bb0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hon.2440_4","article-title":"Phase 3 study of ibrutinib in combination with ventoclax in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"35","author":"Tam","year":"2017","journal-title":"Hematol Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406817302692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406817302692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T04:15:55Z","timestamp":1570594555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406817302692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1879406817302692"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2017.12.001","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of mantle cell lymphoma in older adults","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}